Research programme: anticancer therapeutics - Galaxy Biotech

Drug Profile

Research programme: anticancer therapeutics - Galaxy Biotech

Alternative Names: Anti-DR4 mAbs; Anti-DR5 mAbs; Anti-FGF2 mAbs; Anti-FGFR2 mAbs; Bispecific antibodies of DR-4 mAbs; Bispecific antibodies of DR-5 mAbs; GAL-F2; GAL-F2 mAb; GAL-F21 mAb; GAL-FR21; HuD-114; HuG-4.2; HuGAL-F2; HuGAL-FR21

Latest Information Update: 19 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Galaxy Biotech
  • Class Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Death domain receptor agonists; Fibroblast growth factor inhibitors; Fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 20 Jun 2011 Research programme: anticancer monoclonal antibodies - Galaxy Biotech is available for licensing as of 20 Jun 2011. http://galaxybiotech.com
  • 06 Apr 2011 Preclinical pharmacodynamics data in Cancer presented at the 102nd Annual Meeting of the American Association for Cancer Research (102nd-AACR-2011) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top